首页> 美国卫生研究院文献>QJM: An International Journal of Medicine >The penumbra of thalidomide the litigation culture and the licensing of pharmaceuticals
【2h】

The penumbra of thalidomide the litigation culture and the licensing of pharmaceuticals

机译:沙利度胺半影诉讼文化和药品许可

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fifty years ago several thousand children were born with severe limb defects after their mothers had been given thalidomide in pregnancy. This tragedy caused procedures for licensing new medicines to become much stricter. Where, nevertheless, significant side effects were found it became common to sue for damages. These consequences have caused possibly an even greater disaster damaging many more people and threatening ruin to health services everywhere. The huge increase in both time and cost in bringing medicines to market is increasing their price to unsupportable levels; and only wealthy companies are now able to do so. This requires reform as does litigation for ‘statistical’ harmful effects.
机译:五十年前,数千名儿童的母亲在怀孕期间接受沙利度胺治疗后出生,患有严重的肢体缺陷。这场悲剧使新药的许可程序变得更加严格。但是,在发现明显副作用的地方,提起诉讼要求赔偿已经很普遍。这些后果可能造成了更大的灾难,更多的人受到伤害,并威胁到各地的卫生服务。将药品推向市场的时间和成本的巨大增加,将其价格提高到了无法支持的水平;现在只有富裕的公司才能这样做。这就需要进行改革,如针对“统计”有害影响的诉讼一样。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号